440 related articles for article (PubMed ID: 32413051)
1. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
Entchev E; Jantzen I; Masson P; Bocart S; Bournique B; Luccarini JM; Bouchot A; Lacombe O; Junien JL; Broqua P; Tallandier M
PLoS One; 2020; 15(5):e0233032. PubMed ID: 32413051
[TBL] [Abstract][Full Text] [Related]
2. MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment.
Entchev E; Antonelli S; Mauro V; Cimbolini N; Jantzen I; Roussey A; Germain JM; Zhang H; Luccarrini JM; Lacombe O; Young SP; Feraille L; Tallandier M
Mol Genet Metab; 2022 Feb; 135(2):143-153. PubMed ID: 34417096
[TBL] [Abstract][Full Text] [Related]
3. Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models.
Tuyaa-Boustugue P; Jantzen I; Zhang H; Young SP; Broqua P; Tallandier M; Entchev E
Mol Genet Metab Rep; 2023 Dec; 37():101011. PubMed ID: 38053941
[TBL] [Abstract][Full Text] [Related]
4. Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil.
Guffon N; Chowdary P; Teles EL; Hughes D; Hennermann JB; Huot-Marchand P; Faudot-Vernier E; Lacombe O; Fiquet A; Richard MP; Abitbol JL; Tallandier M; Hendriksz CJ
J Inherit Metab Dis; 2022 Mar; 45(2):340-352. PubMed ID: 34910312
[TBL] [Abstract][Full Text] [Related]
5. Sensory-motor behavioral characterization of an animal model of Maroteaux-Lamy syndrome (or Mucopolysaccharidosis VI).
Saccone P; Cotugno G; Russo F; Mastrogiacomo R; Tessitore A; Auricchio A; De Leonibus E
Sci Rep; 2014 Jan; 4():3644. PubMed ID: 24407717
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of clinical features and arylsulfatase B gene mutation in thirteen Chinese children with mucopolysaccharidosis type VI].
Zheng J; Huang Y; Zhao X; Sheng H; Cheng J; Zhou Z; Li X; Mao X; Liu L
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):403-8. PubMed ID: 25190157
[TBL] [Abstract][Full Text] [Related]
7. Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.
Maccari F; Rigon L; Mantovani V; Galeotti F; Salvalaio M; D'Avanzo F; Zanetti A; Capitani F; Gabrielli O; Tomanin R; Volpi N
J Mol Med (Berl); 2022 Aug; 100(8):1169-1179. PubMed ID: 35816218
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
[TBL] [Abstract][Full Text] [Related]
9. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.
Zhang H; Wood T; Young SP; Millington DS
Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519
[TBL] [Abstract][Full Text] [Related]
10. Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI.
Evers M; Saftig P; Schmidt P; Hafner A; McLoghlin DB; Schmahl W; Hess B; von Figura K; Peters C
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8214-9. PubMed ID: 8710849
[TBL] [Abstract][Full Text] [Related]
11. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses.
Simonaro CM; Haskins ME; Schuchman EH
Lab Invest; 2001 Sep; 81(9):1319-28. PubMed ID: 11555679
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of Glycosaminoglycans (GAG) accumulation in patients with mucopolysaccharidosis type VI-LeukoGAG, Corneal Opacification (COM) and Carotid Intima Media Thickening (CIMT).
Sohn YB; Wang R; Ashworth J; Broqua P; Tallandier M; Abitbol JL; Jozwiak E; Pollard L; Wood TC; Aslam T; Harmatz PR
Mol Genet Metab Rep; 2024 Mar; 38():101041. PubMed ID: 38234862
[TBL] [Abstract][Full Text] [Related]
13. Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): a single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation.
Whitley CB; Utz JR
Mol Genet Metab; 2010 Dec; 101(4):346-8. PubMed ID: 20800524
[TBL] [Abstract][Full Text] [Related]
14. Hepatic storage of glycosaminoglycans in feline and canine models of mucopolysaccharidoses I, VI, and VII.
Haskins ME; Otis EJ; Hayden JE; Jezyk PF; Stramm L
Vet Pathol; 1992 Mar; 29(2):112-9. PubMed ID: 1632054
[TBL] [Abstract][Full Text] [Related]
15. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
Harmatz P; Hendriksz CJ; Lampe C; McGill JJ; Parini R; Leão-Teles E; Valayannopoulos V; Cole TJ; Matousek R; Graham S; Guffon N; Quartel A;
Mol Genet Metab; 2017 Sep; 122(1-2):107-112. PubMed ID: 28457718
[TBL] [Abstract][Full Text] [Related]
16. Characterization of dermatan sulfate in mucopolysaccharidosis VI. Evidence for the absence of hyaluronidase-like enzymes in human skin fibroblasts.
Klein U; von Figura K
Biochim Biophys Acta; 1980 Jun; 630(1):10-4. PubMed ID: 6770909
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis of 105 mucopolysaccharidosis type VI patients.
Karageorgos L; Brooks DA; Pollard A; Melville EL; Hein LK; Clements PR; Ketteridge D; Swiedler SJ; Beck M; Giugliani R; Harmatz P; Wraith JE; Guffon N; Leão Teles E; Sá Miranda MC; Hopwood JJ
Hum Mutat; 2007 Sep; 28(9):897-903. PubMed ID: 17458871
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats.
Auclair D; Finnie J; Walkley SU; White J; Nielsen T; Fuller M; Cheng A; O'Neill CA; Hopwood JJ
Pediatr Res; 2012 Jan; 71(1):39-45. PubMed ID: 22289849
[TBL] [Abstract][Full Text] [Related]
19. Cardiac and ocular pathologies in a mouse model of mucopolysaccharidosis type VI.
Strauch OF; Stypmann J; Reinheckel T; Martinez E; Haverkamp W; Peters C
Pediatr Res; 2003 Nov; 54(5):701-8. PubMed ID: 12904606
[TBL] [Abstract][Full Text] [Related]
20. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.
Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S
Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
